
## Paola Vacca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2757238/publications.pdf Version: 2024-02-01



Ρλοι Α ΜΑςςΑ

#	Article	IF	CITATIONS
1	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Modern Pathology, 2022, 35, 376-385.	5.5	19
2	Glucocorticoids inhibit human hematopoietic stem cell differentiation toward a common ILC precursor. Journal of Allergy and Clinical Immunology, 2022, 149, 1772-1785.	2.9	5
3	NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 2021, 80, 100870.	6.4	134
4	Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. Journal of Allergy and Clinical Immunology, 2021, 147, 349-360.	2.9	65
5	Identification of neuroblastoma cell lines with uncommon TAZ <sup>+</sup> /mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells. , 2021, 9, e001313.		14
6	Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT. Frontiers in Immunology, 2021, 12, 638841.	4.8	34
7	NK Cells and PMN-MDSCs in the Graft From G-CSF Mobilized Haploidentical Donors Display Distinct Gene Expression Profiles From Those of the Non-Mobilized Counterpart. Frontiers in Immunology, 2021, 12, 657329.	4.8	11
8	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973.	4.8	20
9	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123.	4.1	61
10	Wilms' Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages. Cancers, 2021, 13, 224.	3.7	11
11	Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. Journal of Hematology and Oncology, 2021, 14, 191.	17.0	39
12	Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. Frontiers in Immunology, 2021, 12, 803014.	4.8	13
13	PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. Leukemia, 2020, 34, 932-937.	7.2	26
14	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285.	3.7	85
15	Helper Innate Lymphoid Cells in Allogenic Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease. Frontiers in Immunology, 2020, 11, 582098.	4.8	7
16	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156.	4.8	49
17	Characterisation of innate lymphoid cell subsets infiltrating colorectal carcinoma. Gut, 2020, 69, 2261-2263.	12.1	13
18	Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor. Cancers, 2020, 12, 661.	3.7	96

PAOLA VACCA

#	Article	IF	CITATIONS
19	An Anti-inflammatory microRNA Signature Distinguishes Group 3 Innate Lymphoid Cells From Natural Killer Cells in Human Decidua. Frontiers in Immunology, 2020, 11, 133.	4.8	15
20	Increased Arginase1 expression in tumor microenvironment promotes mammary carcinogenesis via multiple mechanisms. Carcinogenesis, 2020, 41, 1695-1702.	2.8	1
21	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177, 2889-2903.	5.4	10
22	TCRαβ/CD19 depleted hematopoietic stem cell transplantation from haploidentical donors: dissecting the GvL/GvHD conundrum. Bone Marrow Transplantation, 2020, 55, 1483-1484.	2.4	1
23	PD-L1 expression in non–small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Human Pathology, 2019, 90, 54-59.	2.0	23
24	Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Frontiers in Immunology, 2019, 10, 957.	4.8	88
25	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Frontiers in Immunology, 2019, 10, 910.	4.8	54
26	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.6	11
27	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PDâ€l receptor. International Journal of Cancer, 2019, 145, 1660-1668.	5.1	65
28	Heterogeneity of NK Cells and Other Innate Lymphoid Cells in Human and Murine Decidua. Frontiers in Immunology, 2019, 10, 170.	4.8	65
29	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441.	10.5	327
30	PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. Mucosal Immunology, 2019, 12, 624-631.	6.0	45
31	PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncolmmunology, 2019, 8, 1557030.	4.6	76
32	Expression of programmed cell death ligand 1 in non–small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathology, 2019, 127, 52-61.	2.4	49
33	Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?. Frontiers in Immunology, 2019, 10, 3140.	4.8	9
34	Exploiting Human NK Cells in Tumor Therapy. Frontiers in Immunology, 2019, 10, 3013.	4.8	37
35	Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?. Immunology Letters, 2018, 201, 14-19.	2.5	50
36	Molecular definition of group 1 innate lymphoid cells in the mouse uterus. Nature Communications, 2018, 9, 4492.	12.8	77

PAOLA VACCA

#	Article	IF	CITATIONS
37	Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua. Frontiers in Immunology, 2018, 9, 1897.	4.8	62
38	PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120.	1.1	135
39	Human Î <sup>3</sup> δT-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias. Frontiers in Immunology, 2018, 9, 984.	4.8	58
40	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. American Journal of Surgical Pathology, 2018, 42, 1384-1389.	3.7	77
41	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget, 2018, 9, 30465-30471.	1.8	26
42	IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid. Oncolmmunology, 2017, 6, e1293210.	4.6	20
43	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	1.5	110
44	IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 140.	8.6	19
45	NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 188.	4.8	45
46	Human NK cells: From surface receptors to clinical applications. Immunology Letters, 2016, 178, 15-19.	2.5	35
47	Human innate lymphoid cells. Immunology Letters, 2016, 179, 2-8.	2.5	52
48	Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. Mucosal Immunology, 2016, 9, 1372-1383.	6.0	99
49	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
50	Proteomic analysis uncovers common effects of IFN-Î <sup>3</sup> and IL-27 on the HLA class I antigen presentation machinery in human cancer cells. Oncotarget, 2016, 7, 72518-72536.	1.8	20
51	MSC and innate immune cell interactions: A lesson from human decidua. Immunology Letters, 2015, 168, 170-174.	2.5	26
52	Identification of diverse innate lymphoid cells in human decidua. Mucosal Immunology, 2015, 8, 254-264.	6.0	151
53	Unique Eomes+ NK Cell Subsets Are Present in Uterus and Decidua During Early Pregnancy. Frontiers in Immunology, 2015, 6, 646.	4.8	107
54	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77

Paola Vacca

#	Article	IF	CITATIONS
55	In vivo generation of decidual natural killer cells from resident hematopoietic progenitors. Haematologica, 2014, 99, 448-457.	3.5	43
56	Development of human natural killer cells and other innate lymphoid cells. Seminars in Immunology, 2014, 26, 107-113.	5.6	56
57	Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications. International Archives of Allergy and Immunology, 2014, 164, 253-264.	2.1	119
58	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica, 2014, 99, 888-896.	3.5	43
59	Stromal Cells from Human Decidua Exert a Strong Inhibitory Effect on NK Cell Function and Dendritic Cell Differentiation. PLoS ONE, 2014, 9, e89006.	2.5	63
60	Natural killer cells in human pregnancy. Journal of Reproductive Immunology, 2013, 97, 14-19.	1.9	63
61	Understanding human NK cell differentiation: Clues for improving the haploidentical hematopoietic stem cell transplantation. Immunology Letters, 2013, 155, 2-5.	2.5	5
62	NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on shortâ€ŧerm ILâ€⊋ activation. European Journal of Immunology, 2013, 43, 550-561.	2.9	41
63	NK cells from malignant pleural effusions are potent antitumor effectors. Oncolmmunology, 2013, 2, e23638.	4.6	14
64	Origin, phenotype and function of human natural killer cells in pregnancy. Trends in Immunology, 2011, 32, 517-523.	6.8	138
65	CD34 <sup>+</sup> hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2402-2407.	7.1	195
66	Crosstalk between decidual NK and CD14 <sup>+</sup> myelomonocytic cells results in induction of Tregs and immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11918-11923.	7.1	220
67	Targeting α7-nicotinic receptor for the treatment of pleural mesothelioma. European Journal of Cancer, 2008, 44, 2296-2311.	2.8	29
68	Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. International Immunology, 2008, 20, 1395-1405.	4.0	95
69	Generation of a Novel Regulatory NK Cell Subset from Peripheral Blood CD34+ Progenitors Promoted by Membrane-Bound IL-15. PLoS ONE, 2008, 3, e2241.	2.5	42
70	Analysis of Natural Killer Cells Isolated from Human Decidua: Evidence that 2B4 (CD244) Functions as an Inhibitory Receptor and Blocks NK Cell Function. Clinical Immunology, 2007, 123, S187.	3.2	3
71	Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E. Journal of Immunological Methods, 2007, 322, 128-136.	1.4	7
72	Analysis of natural killer cells isolated from human decidua: evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood, 2006, 108, 4078-4085.	1.4	117

PAOLA VACCA

#	Article	IF	CITATIONS
73	OR.69. Hla-E-Restricted Cytolytic T Lymphocytes: Their Role in Cytomegalovirus Infection and Transplantation. Clinical Immunology, 2006, 119, S29-S30.	3.2	0
74	Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology, 2005, 35, 3240-3247.	2.9	76
75	Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. BMC Immunology, 2004, 5, 21.	2.2	5
76	Early postnatal skin colour changes in term newborns with subclinical histological chorioamnionitis. European Journal of Pediatrics, 2004, 163, 550-554.	2.7	9
77	Minimal handling and bronchopulmonary dysplasia in extremely low-birth-weight infants. European Journal of Pediatrics, 2003, 162, 227-229.	2.7	25
78	Small thymus at birth and neonatal outcome in very-low-birth-weight infants. European Journal of Pediatrics, 2003, 162, 204-206.	2.7	13
79	CD157, the Janus of CD38 but with a unique personality. Cell Biochemistry and Function, 2002, 20, 309-322.	2.9	49